上海博研生物工程研究中心為您現(xiàn)貨提供*的產(chǎn)品與服務(wù)，本中心產(chǎn)品齊全，保證實(shí)驗(yàn)的有效性，提供，是您科研實(shí)驗(yàn)產(chǎn)品的一站式平臺，咨詢。！

產(chǎn)品名稱：Anti-HPV16 E6 protein抗體,人類乳頭狀瘤病毒16抗體勁爆優(yōu)惠
中文名稱：人類乳頭狀瘤病毒16抗體
英文名稱：Anti-HPV16 E6 protein
產(chǎn)品編號：BYK-0990R
產(chǎn)品別名：E6; HPV16 E6 protein; Human Papilloma Virus; Human papillomavirus type 16 E6; Human papillomavirus type 16; Protein E6; E6 protein; HPV16 E6; HPV16-E6; VE6_HPV16.

本公司另供應(yīng)“人類乳頭狀瘤病毒16抗體”的標(biāo)記有：Alexa Fluor 350 Alexa Fluor 488 Alexa Fluor 555 Alexa Fluor 647 AP APC Biotin Cy3 Cy5 Cy5.5 Cy7 FITC Gold HRP PE PE-Cy3 PE-CY5 PE-CY5.5 PE-CY7 RBITC.
產(chǎn)品規(guī)格：100ug/200ug
產(chǎn)品濃度： 1mg/1ml
抗體來源：兔源、鼠源、山羊
克 隆：單克隆抗體、多克隆抗體
抗體類型：一抗
性 狀： 凍干粉或液體
保存條件：Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Anti-HPV16 E6 protein抗體,人類乳頭狀瘤病毒16抗體勁爆優(yōu)惠技術(shù)說明，產(chǎn)品*，由于篇幅原因，更多信息請：

ANti-V5 tag（recombinant V5-tagged proteins polyclonal）  V5 tag標(biāo)簽抗體
Anti-KT3 tag  KT3 tag標(biāo)簽抗體
Anti-VSV-G tag（vesicular stomatitis virus glycoprotein）  VSV-G tag標(biāo)簽抗體
Anti-HIV gp120  艾滋病病毒抗體
Anti-HIV gp41  艾滋病病毒抗體
Anti-HIV-1 ENV （gp160） antigen/envelope glycoprotein  艾滋病病毒-1包膜糖蛋白抗體
Anti-HIV-1 ENV （gp160） antigen/envelope glycoprotein  艾滋病病毒-1包膜糖蛋白抗體
Anti-HLA-DR （human leukoyte Antigen DR）  HLA-DR抗原抗體
Anti-HLA-G （Human Leukocyte Anti-gen-G）  人類白細(xì)胞抗原G/組織相容性白細(xì)胞抗原G抗體
Anti-HMGB4（High Mobility Group Box protein 4）  高遷移率族蛋白B4抗體
Anti-HNF-1α（Hepatocyte nuclear factor 1α）  肝細(xì)胞核因子1α抗體
Anti-HO-1/HSP32 （Hemeo xygenase 1）  血紅素氧合酶-1/熱休克蛋白-32抗體
Anti-HO-2 （Heme oxygenase 2）  血紅素氧合酶-2抗體
Anti-HOXc8  同源盒基因的一種
Anti-HPA（heparanase）  抗乙酰肝素酶抗體
Anti-phospho-HP1（pTyr）（phospho-heterochromatin protein 1）（fruit fly）  抗異染色質(zhì)蛋白1磷酸化抗體（果蠅）
Anti-HOXA10 （homeobox protein A10）  HOXA10抗體

產(chǎn)品介紹：

Human papilloma viruses （HPVs） can be classified as either high risk or low risk according to their association with cancer. HPV16 and HPV18 are the most common of the high risk group while HPV6 and HPV11 are among the low risk types. Approximay 90% of cervical cancers contain HPV DNA of the high risk types. Mutational analysis have shown that the E6 and E7 genes of the high risk HPVs are necessary and sufficient for HPV transforming function. The specific interactions of the E6 and E7 proteins with p53 and pRB, respectively, correlate with HPV high and low risk classifications. The high risk HPV E7 proteins bind to pRB with a higher affinity than do the low risk HPV proteins, and only the high risk HPV E6 proteins form detectable complexes with p53 in vitro.